Stay updated on AXS-05 in Treatment-Resistant Major Depressive Disorder Clinical Trial

Sign up to get notified when there's something new on the AXS-05 in Treatment-Resistant Major Depressive Disorder Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the AXS-05 in Treatment-Resistant Major Depressive Disorder Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the efficacy and safety evaluation of AXS-05 relative to bupropion in subjects with treatment resistant major depressive disorder (MDD). This change may reflect new data or findings in the ongoing clinical trial STRIDE-1.
    Difference
    0.1%
    Check dated 2024-06-06T14:43:25.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying conditions such as meeting DSM-V criteria for MDD, having a history of inadequate response to antidepressant treatments, and a BMI range of 18-40 kg/m2. Previously, no information was provided under Participation Criteria.
    Difference
    13%
    Check dated 2024-05-22T21:25:15.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:14:54.000Z thumbnail image

Stay in the know with updates to AXS-05 in Treatment-Resistant Major Depressive Disorder Clinical Trial

Enter your email address, and we'll notify you when there's something new on the AXS-05 in Treatment-Resistant Major Depressive Disorder Clinical Trial page.